Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis (NCT04507763), a registered phase not stated study. The primary outcome is Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12.

2. Clinical Question

The comparison is about timing of referral among patients receiving the treatment, not a randomized comparison of etanercept against no etanercept or another treatment. The registry record does not state how participants came to be referred at different times, whether the groups were comparable before treatment, or which factors were considered in the analysis. Those details matter because differences between groups may reflect more than referral timing.

The stated primary endpoint is change from baseline in BASFI total score at Month 12. BASFI measures functional limitation related to ankylosing spondylitis, with higher scores indicating worse function. However, the registry record does not report the group-specific changes, their uncertainty, or a statistical comparison. The question can therefore be described from the registered endpoint and group definitions, but the magnitude and precision of any observed difference cannot be assessed from the registry record.

3. Trial Design

The study is titled as an evaluation of early biological treatment in ankylosing spondylitis. Its official title describes clinical outcomes of early versus delayed management of Iraqi patients with ankylosing spondylitis using etanercept. The brief summary says it evaluates available data from Iraqi patients receiving Enbrel treatment, using data from the Baghdad Teaching Hospital registry. The listed intervention is etanercept.

The registry describes an analysis population consisting of participants whose data were included in a retrospective observation. For the primary outcome, participants were grouped by the interval from diagnosis to referral for etanercept management. Early referral is defined as within or equal to 1 year after diagnosis. The delayed-referral categories are 1.1 to 5 years, 5.1 to 10 years, and greater than 10 years after diagnosis. The record does not describe an untreated or alternative-treatment control group, and it identifies the comparison as not randomized; allocation is not stated. These are therefore groups based on referral timing, rather than assigned treatment arms in a like-for-like randomized comparison.

Enrollment is recorded as 763. The study status is completed, with a start date of 2020-08-01 and a primary completion date of 2020-10-01. The registry record does not report the number analyzed in each referral group or the number with measurements at baseline and Month 12. Enrollment should not be treated as the analysis denominator for the endpoint.

The primary outcome is change from baseline in BASFI total score at Month 12. Its timeframe is described as baseline and Month 12, with a parenthetical note referring to data retrieved and observed in 2 months of the study. How that note relates to the Month 12 endpoint is not explained in the registry record. The record does not report details of data collection, follow-up completeness, or the procedures used to determine change scores.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analysis population included all participants whose data were included in the study for retrospective observation. In this outcome measure, participants were grouped on the basis of early and delayed referral to management of AS with etanercept treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Analysis population included all participants whose data were included in the study for retrospective observation.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12, measured over Baseline, Month 12 [from the data retrieved and observed in 2 months of this study].

The primary endpoint is change from baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) total score at Month 12. BASFI consists of 10 questions about functional limitation in people with ankylosing spondylitis. Each question is scored from 0, no functional impairment, to 10, maximal impairment. The total score is the mean of the 10 question scores and ranges from 0 to 10; higher scores mean worse condition.

A change score describes how a participant's measured score differs between the stated baseline and follow-up assessments. Comparing changes across referral-timing groups can describe whether the groups' average functional scores shifted differently over the measurement period. The registry record identifies the outcome parameter as a mean and its dispersion as a standard deviation. A mean gives a group-level average, while a standard deviation describes the spread of participant scores around that average. Neither statistic alone gives the precision of a between-group comparison; that requires an estimate of the contrast and an uncertainty measure such as a confidence interval.

BASFI is used as an endpoint because it quantifies functional limitation relevant to ankylosing spondylitis in a defined score. The registry record does not report the group means, standard deviations, change estimates, confidence intervals, or test results. As a result, the endpoint's scale and intended interpretation are clear, but the registry record does not show the magnitude or precision of the observed changes.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies the primary endpoint as a continuous measure summarized by a mean and standard deviation. It does not report the statistical analysis plan or the method used for the primary comparison. The explanations below describe general statistical concepts relevant to this type of endpoint; they should not be read as a claim that a particular method was used in this study.

What does a mean change represent?

For a continuous score such as BASFI, a mean change is an average of participant-level changes between baseline and follow-up. The group mean describes the average change for the analyzed participants, while the standard deviation describes variation in their changes or scores, depending on which quantity is summarized. The registry record lists standard deviation as the dispersion measure but does not state the detailed calculation or provide the actual values. A group mean does not imply that every participant experienced a change of that size.

A between-group analysis should distinguish each group's change from the contrast between groups. The clinically relevant statistical comparison for a timing question is generally the difference in mean change between referral groups, or another explicitly defined contrast. Reporting only separate group summaries would not fully describe the uncertainty in that contrast. The registry record does not report the contrast or its uncertainty.

What does a confidence interval add?

In general, a confidence interval gives a range of values compatible with the data and the statistical procedure used, expressing uncertainty around an estimate. For a group contrast, it helps readers assess both the possible magnitude and the precision of the estimated difference. A narrow interval indicates greater precision than a wide interval, all else equal. A confidence interval is not a guarantee that the true value lies in the interval, and its interpretation depends on the analysis assumptions. No confidence interval for the primary endpoint is reported in the registry record.

Why does the comparison structure matter?

The endpoint groups are defined by time from diagnosis to referral, not by random assignment. In general, nonrandomized groups can differ in characteristics that affect both the timing of referral and later outcomes. A crude comparison of means may therefore combine any association with referral timing and differences in group composition. Adjustment for measured covariates can address some differences if appropriately specified and measured, but it cannot automatically remove bias from unmeasured factors. The registry record does not report whether adjustment was used, which covariates were considered, or how the analysis was specified.

Repeated measurements also require attention to the relationship between baseline and follow-up scores. General approaches may compare change scores or model follow-up scores while accounting for baseline. Their interpretation and assumptions differ. The registry record identifies change from baseline as the endpoint but does not explain the estimator or model. It also does not report how repeated measurements or participants with only one measurement were handled.

What role does variability play?

Standard deviation describes the spread of observed values among participants; it is not the same as the standard error, which describes uncertainty in an estimated mean. The standard error and confidence interval depend on the amount of information in the analysis as well as variability. Because analysis counts and standard deviations are not reported, readers cannot reconstruct precision from the enrollment figure. The registry record's enrollment of 763 is not necessarily the number with usable baseline and Month 12 data.

General statistical analyses may also depend on distributional assumptions. If a continuous outcome has strongly asymmetric values or influential observations, a mean-based analysis can be sensitive to those features. The BASFI score is bounded from 0 to 10, which defines its possible scale, but the record does not report the observed score distributions or diagnostics. No assessment of model fit or distributional assumptions is reported.

How should planning illustrations be understood?

The record describes planning illustrations based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustrated effect is described as a stated fraction of the observed effect. These are planning assumptions, not evidence that the study was designed using those assumptions. The registry record does not report a sample-size justification for the study's own design, and no sample-size illustration values are included in the record. A planning calculation estimates the sample size associated with specified assumptions; it is not observed power and does not replace reporting the estimated effect and its uncertainty.

Because the primary comparison involves four referral-timing categories, a two-arm planning illustration may not represent the full structure of the endpoint comparison. The registry record does not explain how the planning illustration relates to the analysis groups. It also does not report whether a particular pairwise contrast or an overall comparison was prespecified. Readers should not infer the analysis strategy from planning assumptions alone.

Finally, interpretation should separate statistical significance from effect magnitude and precision. A p-value, if reported, would address how compatible the observed data are with a specified statistical null model under its assumptions; it would not indicate the probability that the null hypothesis is true or establish causation. The record reports no p-value or effect estimate for the primary endpoint. The available information therefore supports describing the endpoint and the general statistical considerations, but not evaluating the primary result quantitatively.

10. Multiplicity, Missing Data and Analysis Populations

The primary endpoint is identified, but the registry record does not report whether the study specified multiple primary comparisons, a testing hierarchy, or an adjustment for multiplicity. There are four referral-timing categories, which permit more than one possible group contrast, but the record does not state which comparisons were planned or which were treated as primary. Without that information, the family of statistical tests and any control of false-positive findings cannot be assessed. The record lists two outcome measures and two analyses, but it does not provide further details about their relationship or testing strategy.

Missing-data handling is not reported in the registry record. It does not state how many participants had BASFI measurements at baseline or Month 12, how many had incomplete data, or whether the analysis used complete cases, imputation, or another method. It also does not describe assumptions about why data might be missing. These details affect both the analyzed population and the interpretation of estimates, especially if outcome availability differs across referral groups.

The endpoint population is described as all participants whose data were included in the retrospective observation. That description does not identify a count or establish that every enrolled participant contributed to the endpoint. The registry record does not report the number analyzed in each group, exclusions, or reasons for exclusion. Enrollment of 763 should therefore not be interpreted as the denominator for the primary outcome.

Analysis populations are not described beyond the retrospective-observation statement. The record does not specify an intention-to-treat population, a per-protocol population, or another formal analysis set. Since treatment allocation is not stated and the groups are based on referral timing, the precise membership and handling of participants who may not fit a group definition are also not reported.

11. What the Result Does, and Does Not, Mean

The registry record identifies an important descriptive question: whether BASFI functional scores changed differently across groups defined by how soon patients were referred to etanercept management after diagnosis. It establishes the score's meaning, its scale, the group definitions, and the intended Month 12 endpoint. These details clarify what the analysis was intended to address.

The record does not, however, report the numerical primary outcome. It therefore does not show whether mean BASFI scores increased or decreased, how large any changes were, or how different the groups were. It also provides no confidence intervals, p-values, or group-specific analysis counts. Statistical significance, precision, and the practical magnitude of the result cannot be evaluated from the registry record.

Even a reported difference between the timing groups would not automatically show that earlier referral caused a difference in functional outcome. The comparison is not randomized, and allocation is not stated. The registry record does not describe how referral timing was determined or what adjustment was made for differences between groups. Any observed group contrast would need to be interpreted in light of those design and analysis details.

The score is bounded between 0 and 10, with higher values indicating worse functional limitation. That direction helps interpret a reported estimate, but no estimate is available in the registry record. The endpoint description is not itself evidence that one group had better outcomes. Likewise, the listed adverse-event zeros do not establish absence of events: the entry also records zero participants at risk, so it does not provide a meaningful event rate for an observed group.

In short, the record supports an account of the intended comparison, not a conclusion about its result. Establishing the direction, size, and uncertainty of the observed association would require numerical outcome summaries and fuller information about analysis populations, missing data, and methods.

12. Why This Trial Matters Statistically

This study is statistically notable for framing a treatment-timing question within a registry-based retrospective observation. The central comparison is among patients receiving etanercept, categorized by the interval from diagnosis to referral. That is a different question from whether etanercept is better than no treatment or another therapy, and it calls for careful interpretation of group comparability.

The primary endpoint, BASFI change, is a continuous functional score with a defined range and direction. Those features make the intended clinical construct and the meaning of a numerical estimate understandable. At the same time, interpretation depends on more than identifying the endpoint: group summaries, a direct contrast, uncertainty, and analysis denominators are needed to judge the evidence. Those numerical results are not reported in the registry record.

The record also illustrates why enrollment and endpoint analysis counts should not be conflated. Enrollment is recorded as 763, but the number with usable baseline and Month 12 data, and the distribution across referral groups, are not reported. Without those counts, neither attrition nor precision can be assessed. Likewise, a nonrandomized timing comparison raises questions about differences between groups, but the adjustment strategy is not reported.

Finally, the listed Month 12 timeframe is accompanied by a note about data retrieved and observed in 2 months. The record does not clarify that timing description. Reporting how measurement times were defined, which data were analyzed, and how incomplete follow-up was handled would help readers judge the endpoint's interpretability. These statistical details matter because they determine what conclusions an observed difference could support.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report numerical results for the primary endpoint. The absence of group-specific means, standard deviations, change estimates, confidence intervals, and p-values prevents assessment of the observed direction, magnitude, or precision. It also does not report endpoint analysis counts, so the recorded enrollment of 763 cannot be used to infer how much information contributed to the primary comparison.

The comparison is not randomized, and allocation is not stated. Referral timing may be associated with differences among participants, but the registry record does not describe group characteristics or any adjustment for potential confounding. It also does not report the statistical model, covariates, or prespecified contrasts. Consequently, the extent to which a group difference would reflect referral timing rather than other differences cannot be assessed.

Missing-data methods and analysis populations are not reported. The registry record does not state how many baseline or Month 12 measurements were missing, how incomplete observations were treated, or whether the analyzed participants differed from those not included. The record's description of participants whose data were included in retrospective observation does not resolve these questions.

There is also an unresolved timing description: the primary endpoint is identified as Month 12, while the timeframe includes a note about data retrieved and observed in 2 months of the study. The record does not explain how these statements fit together. Finally, the adverse-event entry reports zero at-risk and affected counts, so it does not support interpreting the zeros as evidence of no events in a defined population.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis — NCT04507763.
• Registry record last updated 2021-10-28; status last verified 2021-09.
• Results first posted 2021-10-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

The registry describes a completed study of Iraqi patients with ankylosing spondylitis who received etanercept, using data from the Baghdad Teaching Hospital registry. It records enrollment as 763, a start date of 2020-08-01, and a primary completion date of 2020-10-01. The primary endpoint is change from baseline in BASFI total score at Month 12.

For this outcome, participants are grouped by time from diagnosis to referral: early referral at <= 1 year and delayed referral at 1.1 to 5 years, 5.1 to 10 years, or > 10 years. The comparison is not randomized, and allocation is not stated. Numerical endpoint results, analysis counts, missing-data procedures, and the statistical analysis plan are not reported in the registry record. The timeframe also includes an unexplained note about data retrieved and observed in 2 months.